| 0 (0%) | 06-28 18:07 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.26  |
1-year : | 6.15 |
| Resists | First : | 4.5 |
Second : | 5.26 |
| Pivot price | 3.89 |
|||
| Supports | First : | 3.42 |
Second : | 2.75 |
| MAs | MA(5) : | 4.1 |
MA(20) : | 3.66 |
| MA(100) : | 3.95  |
MA(250) : | 3.89 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 86 |
D(3) : | 77.1 |
| RSI | RSI(14): 67.2 |
|||
| 52-week | High : | 6.13 | Low : | 2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ STRO ] has closed below upper band by 8.6%. Bollinger Bands are 5.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.51 - 4.53 | 4.53 - 4.55 |
| Low: | 4.2 - 4.22 | 4.22 - 4.24 |
| Close: | 4.46 - 4.49 | 4.49 - 4.52 |
Wed, 05 May 2021
Agreement to acquire TESARO - GSK
Mon, 03 Dec 2018
Tesaro Stock Soars After Announcing Agreeing to Be Bought By Glaxosmithkline - Warrior Trading News
Mon, 03 Dec 2018
GlaxoSmithKline Makes $5.1 Billion Play for Cancer Drug Specialist Tesaro - TheStreet
Mon, 03 Dec 2018
GlaxoSmithKline to acquire Tesaro for $4.16 billion - MarketWatch
Wed, 24 Oct 2018
TESARO and Actress Cobie Smulders Launch Not on My Watch, a - GlobeNewswire
Tue, 13 Feb 2018
3 Biotech Stocks Facing Steep Declines Ahead - Investopedia
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 82 (M) |
| Shares Float | 60 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 72.8 (%) |
| Shares Short | 3,230 (K) |
| Shares Short P.Month | 1,900 (K) |
| EPS | -1.88 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.57 |
| Profit Margin | -74.7 % |
| Operating Margin | -435.1 % |
| Return on Assets (ttm) | -17.1 % |
| Return on Equity (ttm) | -81.2 % |
| Qtrly Rev. Growth | 2.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.88 |
| EBITDA (p.s.) | -1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -115 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -2.39 |
| PEG Ratio | 0 |
| Price to Book value | 2.85 |
| Price to Sales | 2.38 |
| Price to Cash Flow | -3.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|